13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-002562-19-IT
(EUCTR)
21/04/200624/01/2007Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHTImmunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT VERIFICARE Patients with multiple sclerosis, age between 18 and 50
MedDRA version: 6.1;Level: PT;Classification code 10028245
Trade Name: L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE
Product Name: Thymoglobuline
INN or Proposed INN: Antithymocyte
Trade Name: Endoxan - ciclofosfamide
Product Name: Endoxan
INN or Proposed INN: Cyclophosfamide
Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di GenovaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Italy